Articles from Allegro NV

Liege, Belgium – 4 March 2025 (08:30 CET) – Allegro NV, a biomedical company developing a transformative nanotechnology-based treatment for degenerative joint disease, announced today that hydrocelin (ALG-001), its lead injectable microparticle hydrogel, has been found safe in three preclinical studies. The studies found no signs of pyrogenicity, irritation or delayed sensitization in the test groups, strengthening hydrocelin’s safety profile after two earlier preclinical studies announced in December. Allegro intends to launch a multi-center pivotal trial in osteoarthritis patients in Belgium later this year.

Liege, Belgium – 11 December 2024 (07:30 CET) – Allegro NV, a biomedical company developing transformative nanotechnology-based devices for degenerative joint disease, today announced that its injectable microparticle gel, hydrocelin, has demonstrated favorable safety in two preclinical studies. The gel contains cross-linked microparticles that act as tiny shock absorbers in the synovial fluid. This reduces the force on sensitive nerve endings to provide immediate pain relief and starts to protect cartilage. Allegro intends to advance hydrocelin into multi-center pivotal clinical studies in osteoarthritis patients in 2025.